全文获取类型
收费全文 | 75367篇 |
免费 | 5844篇 |
国内免费 | 1377篇 |
专业分类
耳鼻咽喉 | 498篇 |
儿科学 | 3666篇 |
妇产科学 | 1133篇 |
基础医学 | 7953篇 |
口腔科学 | 1051篇 |
临床医学 | 9800篇 |
内科学 | 11108篇 |
皮肤病学 | 789篇 |
神经病学 | 2348篇 |
特种医学 | 1711篇 |
外国民族医学 | 3篇 |
外科学 | 9796篇 |
综合类 | 10807篇 |
现状与发展 | 9篇 |
预防医学 | 11631篇 |
眼科学 | 323篇 |
药学 | 6312篇 |
57篇 | |
中国医学 | 1502篇 |
肿瘤学 | 2091篇 |
出版年
2024年 | 142篇 |
2023年 | 1179篇 |
2022年 | 1873篇 |
2021年 | 3284篇 |
2020年 | 3290篇 |
2019年 | 2697篇 |
2018年 | 2652篇 |
2017年 | 2563篇 |
2016年 | 2751篇 |
2015年 | 2938篇 |
2014年 | 5193篇 |
2013年 | 5597篇 |
2012年 | 4900篇 |
2011年 | 5128篇 |
2010年 | 3842篇 |
2009年 | 3620篇 |
2008年 | 3498篇 |
2007年 | 3497篇 |
2006年 | 3284篇 |
2005年 | 2882篇 |
2004年 | 2404篇 |
2003年 | 2021篇 |
2002年 | 1510篇 |
2001年 | 1377篇 |
2000年 | 1137篇 |
1999年 | 1074篇 |
1998年 | 883篇 |
1997年 | 809篇 |
1996年 | 688篇 |
1995年 | 662篇 |
1994年 | 636篇 |
1993年 | 536篇 |
1992年 | 508篇 |
1991年 | 442篇 |
1990年 | 369篇 |
1989年 | 354篇 |
1988年 | 296篇 |
1987年 | 252篇 |
1986年 | 242篇 |
1985年 | 284篇 |
1984年 | 207篇 |
1983年 | 150篇 |
1982年 | 204篇 |
1981年 | 150篇 |
1980年 | 108篇 |
1979年 | 94篇 |
1978年 | 77篇 |
1977年 | 76篇 |
1976年 | 72篇 |
1973年 | 34篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
61.
62.
目的评估消化道恶性肿瘤患者的能量消耗,探讨最佳计算公式及能量消耗的影响因素。方法采用连续入组法,纳入2016年3月至2016年12月在陆军军医大学第一附属医院肿瘤科住院治疗患者,运用代谢车测定其静息代谢能量(REE),使用Harris-Benedict公式和30kcal/(kg·d) 公式预测患者的一日总能量消耗(TEE)。收集研究对象的相关指标如年龄、身高、体重、病程、原位癌部位、是否荷瘤等。结果共纳入26例患者,其中包括食管癌11例,胃癌8例,结直肠癌7例,73%的患者处于高代谢状态,约69%的患者处于肿瘤Ⅳ期;其中不同病程和原位癌位置与静息能量消耗有差异,差异具有统计学意义;用30kcal/(kg·d)×体重估算TEE可能并不适用于消瘦的消化道肿瘤患者。结论消化道恶性肿瘤患者大多存在营养不良且处于高代谢状态,在给消化道恶性肿瘤患者提供能量时应适当考虑病程长短、肿瘤分期以及肿瘤部位等因素。尽量使用代谢车估算恶性肿瘤患者的TEE,若没有代谢车条件时,对于能下床活动的消化道恶性肿瘤患者,体质指数(BMI)≥18.5kg/m2者推荐使用30kcal/(kg·d)×实际体重的方法估算TEE,BMI<18.5kg/m2者推荐使用30kcal/(kg·d)×标准体重的方法估算TEE。 相似文献
63.
《European Urology Supplements》2015,14(1):9-11
The main goal in the management of patients with vesicoureteral reflux (VUR) is the preservation of kidney function by minimizing the risk of pyelonephritis. By defining and analyzing the risk factors for each patient depending on age, sex, grade of reflux, lower urinary tract dysfunction, anatomic abnormalities, and kidney status, it is possible to identify those patients with a potential risk of upper urinary tract infection and resulting renal scarring. This paper gives a brief overview of the European Association of Urology guidelines for the management and treatment of VUR in children. These guidelines are based on the best currently available knowledge and evidence. 相似文献
64.
Emmi Helle Aldo Córdova-Palomera Tiina Ojala Priyanka Saha Praneetha Potiny Stefan Gustafsson Erik Ingelsson Michael Bamshad Deborah Nickerson Jessica X. Chong University of Washington Center for Mendelian Genomics Euan Ashley James R. Priest 《Genetic epidemiology》2019,43(2):215-226
Loss of function variants in NOTCH1 cause left ventricular outflow tract obstructive defects (LVOTO). However, the risk conferred by rare and noncoding variants in NOTCH1 for LVOTO remains largely uncharacterized. In a cohort of 49 families affected by hypoplastic left heart syndrome, a severe form of LVOTO, we discovered predicted loss of function NOTCH1 variants in 6% of individuals. Rare or low-frequency missense variants were found in 16% of families. To make a quantitative estimate of the genetic risk posed by variants in NOTCH1 for LVOTO, we studied associations of 400 coding and noncoding variants in NOTCH1 in 1,085 cases and 332,788 controls from the UK Biobank. Two rare intronic variants in strong linkage disequilibrium displayed significant association with risk for LVOTO amongst European-ancestry individuals. This result was replicated in an independent analysis of 210 cases and 68,762 controls of non-European and mixed ancestry. In conclusion, carrying rare predicted loss of function variants in NOTCH1 confer significant risk for LVOTO. In addition, the two intronic variants seem to be associated with an increased risk for these defects. Our approach demonstrates the utility of population-based data sets in quantifying the specific risk of individual variants for disease-related phenotypes. 相似文献
65.
66.
67.
目的:探讨分析肿瘤合并新冠病毒感染患者情况并提出自己的思考与建议。方法:通过统计2020年1月至2020年3月期间纳入的313名本院肿瘤科在新冠疫情期间肿瘤合并感染新冠肺炎患者情况,汇总临床资料,分析患者肺部影像学特点,总结肿瘤合并新冠肺炎病毒感染患者临床特征、预后及转归等,并提出自己建议。结果:科室总共313名患者住院,5名新冠感染患者,新冠病毒肺炎发生率为1.6%,这比之前所报道的武汉市新冠病毒普通人群发生率0.37%要高接近3倍,肿瘤合并新冠患者死亡率接近20%。结论:对于疫情结束初期病房应尽量减少患者非必要往返医院次数,实行肿瘤患者分层管理,加强轻症患者随访,线上管理等;而对于住院患者,则采取缓冲分诊模式,做好病房消毒隔离以及管理,避免感染,减少肿瘤病房新型冠状病毒爆发概率。 相似文献
68.
经皮肺动脉瓣植入术(PPVI)在我国作为一种新兴的技术,开展相对较晚,但随着我国医疗水平的不断提高以及临床对于右心室流出道梗阻的先天性心脏病患者术后出现重度肺动脉瓣反流的不断重视,PPVI在我国得到了飞速发展。近十几年来,欧美国家已在临床成熟应用PPVI,相对于传统外科手术而言其具有微创、可重复性、术后疗效好等优点。现对PPVI在肺动脉瓣反流患者中的临床应用进行叙述。 相似文献
69.
70.
Biliary tract cancer, including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are rare tumours with a rising incidence. Prognosis is poor, since most patients are diagnosed with advanced disease. Only ~20% of patients are diagnosed with early-stage disease, suitable for curative surgery. Despite surgery performed with potentially-curative intent, relapse rates are high, with around 60–70% of patients expected to have disease recurrence. Most relapses occur in the form of distant metastases, with a predominance of liver spread. In view of high tumour recurrence, adjuvant strategies have been explored for many years, in the form of radiotherapy, chemo-radiotherapy and chemotherapy. Historically, few randomised trials were available, which included a variety of additional tumours (e.g. pancreatic and ampullary tumours); most evidence relied on phase II and retrospective studies, with no high-quality evidence available to define the real benefit derived from adjuvant strategies.Since 2017, three randomised phase III clinical trials have been reported; all recruited patients with resected biliary tract cancer (CCA and GBC) who were randomised to observation alone, or chemotherapy in the form of gemcitabine (BCAT study; included patients diagnosed with extrahepatic CCA only), gemcitabine and oxaliplatin (PRODIGE-12/ACCORD-18; included patients diagnosed with CCA and GBC) or capecitabine (BILCAP; included patients diagnosed with CCA and GBC). While gemcitabine-based chemotherapy failed to show an impact on patient outcome (relapse-free survival (RFS) or overall survival (OS)), the BILCAP study showed a benefit from adjuvant capecitabine in terms of OS (pre-planned sensitivity analysis in the intention-to-treat population and in the per-protocol analysis), with confirmed benefit in terms of RFS. Based on the BILCAP trial, international guidelines recommend adjuvant capecitabine for a period of six months following potentially curative resection of CCA as the current standard of care for resected CCA and GBC. However, BILCAP failed to show OS benefit in the intention-to-treat (non-sensitivity analysis) population (primary end-point), and this finding, as well as some inconsistencies between studies has been criticised and has led to confusion in the biliary tract cancer medical community.This review summarises the adjuvant field in biliary tract cancer, with evidence before and after 2017, and comparison between the latest randomised phase III studies. Potential explanations are presented for differential findings, and future steps are explored. 相似文献